CXCL1 and cancer: Further, cancer cells can modulate the TME through the secretion of cytokines and chemokines, and the TP53 mutation status drives the expression of CXCL1, CXCL10, and CCL20 (Addadi et al., 2010; Lowe et al., 2014).